HER2 Support Group Forums - View Single Post

R.B. · 03-14-2008, 03:06 AM

Full of Beans

It is not a cheap book about £45 discounted on Amazon but Omega 3 Fatty acid in Clinical Nutrition Heller Stehr and Koch has some interesting observations on long chain Omega three and immune functions and cancer.

In general terms long chain Omega Three seems to improve immune function and dampen inflammatory pressures at the same time.

RE the above

One element from a natural plant may not reflect the overall impact of the whole.

I simply have not looked at this so cannot intelligently comment but re the above trial IL6 increase may be double edged. Excess IL6 is a problem and features as a marker in many inflammatory conditions.

Also see the COX2 related posts.

I have also seen trials that might suggest higher IL6 is not beneficial in BC

http://www.ncbi.nlm.nih.gov/pubmed/16927176

Significance of interleukin-6 (IL-6) in breast cancer (review).
Knüpfer H, Preiss R.

Institute of Clinical Pharmacology, University of Leipzig, Härtelstrasse 16-18, Leipzig, Germany. Heike.Knuepfer@medizin.uni-leipzig.de

Cytokines are factors that are known to have both tumor-promoting and inhibitory effects on breast cancer growth depending presumably on their relative concentrations and the presence of other modulating factors. Different cytokines play an important role in controlling the immune system. Interleukin-6 (IL-6) is a pleiotropic cytokine with obviously tumor-promoting and tumor-inhibitory effects. Here, we review the role of IL-6 in in vitro experiments of breast tumor cells, in breast tumor tissues (BTs) and assess its potential as a prognostic indicator in breast cancer patients. A literature search was conducted using PubMed, restricted to articles published in English language. In summary, results regarding the effect of IL-6 on breast tumor cells and on BTs are not unique indicating both tumor-promoting and inhibitory effects of IL-6. Concerning patients' serum IL-6 levels, data are surprisingly unique showing IL-6 to be a negative prognosticator in breast tumor patients.

PMID: 16927176 [PubMed - indexed for MEDLINE]

RB

03-14-2008, 03:06 AM	#13
R.B. Senior Member Join Date: Mar 2006 Posts: 1,843	Full of Beans It is not a cheap book about £45 discounted on Amazon but Omega 3 Fatty acid in Clinical Nutrition Heller Stehr and Koch has some interesting observations on long chain Omega three and immune functions and cancer. In general terms long chain Omega Three seems to improve immune function and dampen inflammatory pressures at the same time. RE the above One element from a natural plant may not reflect the overall impact of the whole. I simply have not looked at this so cannot intelligently comment but re the above trial IL6 increase may be double edged. Excess IL6 is a problem and features as a marker in many inflammatory conditions. Also see the COX2 related posts. I have also seen trials that might suggest higher IL6 is not beneficial in BC http://www.ncbi.nlm.nih.gov/pubmed/16927176 Significance of interleukin-6 (IL-6) in breast cancer (review). Knüpfer H, Preiss R. Institute of Clinical Pharmacology, University of Leipzig, Härtelstrasse 16-18, Leipzig, Germany. Heike.Knuepfer@medizin.uni-leipzig.de Cytokines are factors that are known to have both tumor-promoting and inhibitory effects on breast cancer growth depending presumably on their relative concentrations and the presence of other modulating factors. Different cytokines play an important role in controlling the immune system. Interleukin-6 (IL-6) is a pleiotropic cytokine with obviously tumor-promoting and tumor-inhibitory effects. Here, we review the role of IL-6 in in vitro experiments of breast tumor cells, in breast tumor tissues (BTs) and assess its potential as a prognostic indicator in breast cancer patients. A literature search was conducted using PubMed, restricted to articles published in English language. In summary, results regarding the effect of IL-6 on breast tumor cells and on BTs are not unique indicating both tumor-promoting and inhibitory effects of IL-6. Concerning patients' serum IL-6 levels, data are surprisingly unique showing IL-6 to be a negative prognosticator in breast tumor patients. PMID: 16927176 [PubMed - indexed for MEDLINE] RB